166 related articles for article (PubMed ID: 29069826)
1. miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3.
Kim TH; Jeong JY; Park JY; Kim SW; Heo JH; Kang H; Kim G; An HJ
Oncotarget; 2017 Sep; 8(42):72788-72800. PubMed ID: 29069826
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
5. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
6. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
7. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
9. Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
Wang L; Zhang Z; Tian H
J Clin Lab Anal; 2023 Jan; 37(1):e24781. PubMed ID: 36550019
[TBL] [Abstract][Full Text] [Related]
10. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a.
Lin H; Shen L; Lin Q; Dong C; Maswela B; Illahi GS; Wu X
Biomed Pharmacother; 2020 Mar; 123():109711. PubMed ID: 31884343
[TBL] [Abstract][Full Text] [Related]
11. Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network.
Huang H; Yan L; Zhong J; Hong L; Zhang N; Luo X
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):275-286. PubMed ID: 35196944
[TBL] [Abstract][Full Text] [Related]
12. CircEXOC6B Suppresses the Proliferation and Motility and Sensitizes Ovarian Cancer Cells to Paclitaxel Through miR-376c-3p/FOXO3 Axis.
Zheng Y; Li Z; Yang S; Wang Y; Luan Z
Cancer Biother Radiopharm; 2022 Nov; 37(9):802-814. PubMed ID: 33006481
[No Abstract] [Full Text] [Related]
13. LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.
An J; Lv W; Zhang Y
Onco Targets Ther; 2017; 10():5377-5390. PubMed ID: 29180871
[TBL] [Abstract][Full Text] [Related]
14. Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136/CBX2 axis in ovarian cancer.
Zhu J; Luo JE; Chen Y; Wu Q
J Ovarian Res; 2021 Oct; 14(1):136. PubMed ID: 34649611
[TBL] [Abstract][Full Text] [Related]
15. CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression.
Huang C; Qin L; Chen S; Huang Q
Anticancer Drugs; 2023 Mar; 34(3):395-404. PubMed ID: 36729852
[TBL] [Abstract][Full Text] [Related]
16. MiR-26a-5p Heightens Breast Cancer Cell Sensitivity to Paclitaxel via Targeting Flap Endonuclease 1.
Cai Y; Zhang T; Chen G; Liu C
Ann Clin Lab Sci; 2023 Jan; 53(1):116-125. PubMed ID: 36889769
[TBL] [Abstract][Full Text] [Related]
17. miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Guan X; Guan Y
Neoplasma; 2020 Sep; 67(5):972-981. PubMed ID: 32412771
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis.
Huang B; Wei M; Hong L
Open Life Sci; 2021; 16(1):667-681. PubMed ID: 34250246
[TBL] [Abstract][Full Text] [Related]
19. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
20. CircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miR‑185‑5p/BMF axis.
Liu Y; Shen Z; Wei X; Gu L; Zheng M; Zhang Y; Cheng X; Fu Y; Lu W
Transl Oncol; 2023 Oct; 36():101746. PubMed ID: 37499410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
